GlassScriptPhysician profile
Goran Rakocevic
NPI 1265474217
$23,584.58
in general payments reported to CMS, 2019-2025
14 companies · $4,412 in 2025
The $4,412 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,490 · 2020: $2,500 · 2021: $500 · 2022: $8,399 · 2023: $555 · 2024: $729 · 2025: $4,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,300 · Food and Beverage: $2,051 · Travel and Lodging: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,300.00 |
| Food and Beverage | $2,050.58 |
| Travel and Lodging | $345.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $8,519.44 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alnylam Pharmaceuticals INC. | $5,351.73 | 2019 | |
| Amgen INC. | $3,927.47 | 2025 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $2,500.00 | 2020 | |
| Zoll Medical Corporation | $600.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $573.69 | 2023-2025 | Ultomiris |
| Tanabe Pharma America, INC. | $550.47 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $500.00 | 2021 | |
| Allergan, INC. | $466.67 | 2019 | |
| Ucb, INC. | $354.70 | 2023-2024 | Rystiggo |
| Akcea Therapeutics, INC. | $121.32 | 2019 | |
| Csl Behring | $119.09 | 2023 | Hizentra |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goran Rakocevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.